SCHEMBL3304422

SCHEMBL3304422

FC(F)(F)c1cc(NC(=S)NCc2ccccc2Cl)cc(C(F)(F)F)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.67
MAX P61244 1/20 0.67
LMNA P02545 5/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
MAPT P10636 8/20 0.63
ALDH1A1 P00352 5/20 0.63
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
HTT P42858 3/20 0.62
NPSR1 Q6W5P4 2/20 0.62
HPGD P15428 2/20 0.54
ALOX12 P18054 4/20 0.53
PPARG P37231 1/20 0.53
NCOA3 Q9Y6Q9 1/20 0.53
TP53 P04637 1/20 0.52
QPCT Q16769 1/20 0.52
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3301650 0.86 MAPT (0.66) MYCMAXLMNASMN1; SMN2MAPT
SCHEMBL3299625 0.81 MYC (1.00) MYCMAXLMNASMN1; SMN2MAPT
SCHEMBL3302805 0.79 MYC (0.67) MYCMAXLMNASMN1; SMN2MAPT
SCHEMBL3300939 0.78 MAPT (0.79) MYCMAXLMNASMN1; SMN2MAPT
SCHEMBL3305997 0.78 MYC (0.74) MYCMAXLMNASMN1; SMN2MAPT
SCHEMBL8134161 0.77 TP53 (0.47) MYCMAXLMNASMN1; SMN2MAPT
SCHEMBL8134160 0.77 TP53 (0.47) MYCMAXLMNASMN1; SMN2MAPT
SCHEMBL6693381 0.76 P2RX1 (0.55) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL26491226 0.75 MAPT (1.00) MYCMAXLMNASMN1; SMN2MAPT
SCHEMBL26491103 0.75 MAPT (0.77) MYCMAXLMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US claimed
EP-2074085-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS Lica Pharmaceuticals A/S (DK) 2009-07-01 EP claimed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO claimed
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
EP-2074085-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS Lica Pharmaceuticals A/S (DK) 2009-07-01 EP disclosed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS TST, TPX2, TPMT MYC 1961/4885MAX 2281/4885LMNA 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.